Floatz logo

IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP

Stage IVA Colon Cancer AJCC v8

M.D. Anderson Cancer Centerprotein_peptidePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Stage IVA Colon Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Tranexamic Acid
Assaf-Harofeh Medical Center
Phase 4BB
Eloxatin
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2BB
FLUOROURACILUM
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2BB
Cetuximab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2B
Regorafenib
City of Hope Medical Center
Phase 2B

View all 34 →

Same molecule, other indications

IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP is also rated in:

Stage IIIA Lung Cancer AJCC v8Dormant
B
Indicative ·
62 / 100
View asset →
oropharyngeal carcinomaDormant
B
Indicative ·
57 / 100
View asset →
reproductive system cancerDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →